Therapy
Female CEOs
Health
Halozyme Therapeutics
$16.769876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$16.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.20 (-1.18%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell HALO and other stocks, options, ETFs, and crypto commission-free!
About HALO
Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Read More It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Employees
281
Headquarters
San Diego, California
Founded
1998
Market Cap
2.47B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
839.77K
High Today
$16.94
Low Today
$16.55
Open Price
$16.94
Volume
427.91K
52 Week High
$18.85
52 Week Low
$13.24
Collections
Therapy
Female CEOs
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Medical
Technology
HALO News
Price Paid on Robinhood
3% Higher
Right Now
52 Week Low
$13.24
Average Price Paid
$16.23
52 Week High
$18.85
Analyst Ratings
45%
of 11 ratings
Buy
45%
Hold
36%
Sell
18%
HALO Earnings
-$0.23
$0.13
$0.49
$0.85
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours